Overview

Cardiovascular Drugs Market is poised to value over CAGR of over 3.8% during the forecast period 2022 to 2028.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Cardiovascular Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Cardiovascular Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Cardiovascular Drugs Market:
• Bristol Mayor Squibb Company
• Pfizer Inc
• Bayer AG
• Janssen Pharmaceuticals, Inc
• Astrazenca
• Sanofi
• Novartis AG
• Merck & Co,Inc.
• Gilead Sciences,Inc.
• F.Hoffman-La Roche Ltd
• Amgen Inc
• Baxter International Inc
• C. H. Boehringer Sohn AG & Co KG
• Johnson & Johnson
 (Note: The list of the major players will be updated with the latest market scenario and trends)

Cardiovascular Drugs Market Segmentation:

By Drug Type
• Antihypertensive
 o Diovan/Co-Diovan, Blopress
 o Benicar/Benicar HCT
 o Micardis/Micardis HCT
 o Aprovel/CoAprovel
 o Tekturna/Rasilez
 o Edarbi
 o Cozaar/Hyzaar
 o Norvasc
 o Exforge/Exforge HCT
 o Coversyl
 o Seloken/Toprol-XL
• Antihyperlipidemic
 o Lipitor
 o Crestor
 o Niaspan
 o TriCor/Trilipix
 o Zetia/Vytorin
 o Tredaptive
• Anticoagulants
• Antiplatelet Drugs
• Others

By Disease Indication
• Hypertension
• Hyperlipidemia
• Coronary Artery Disease
• Arrhythmia
• Others
 
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Cardiovascular Drugs Market By Drug Type,By Disease Indication,By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Drug Type launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Cardiovascular Drugs Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Cardiovascular Drugs Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Cardiovascular Drugs Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Cardiovascular Drugs Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Antihypertensive
       7.1.1. Diovan/Co-Diovan, Blopress
        7.1.2. Benicar/Benicar HCT
        7.1.3. Micardis/Micardis HCT
        7.1.4. Aprovel/CoAprovel
        7.1.5. Tekturna/Rasilez
        7.1.6. Edarbi
        7.1.7. Cozaar/Hyzaar
        7.1.8. Norvasc
        7.1.9. Exforge/Exforge HCT
        7.1.10.Coversyl
        7.1.11.Seloken/Toprol-XL
  7.2. Antihyperlipidemic
       7.2.1. Lipitor
       7.2.2. Crestor
       7.2.3. Niaspan
       7.2.4. TriCor/Trilipix
       7.2.5. Zetia/Vytorin
       7.2.6. Tredaptive
  7.3. Anticoagulants
  7.4. Antiplatelet Drugs
  7.5. Others
 
8. Global Cardiovascular Drugs Market, By Disease Indication Historical Analysis and Forecast 2022-2028 (USD Million)  
  8.1. Hypertension
  8.2. Hyperlipidemia
  8.3. Coronary Artery Disease
  8.4. Arrhythmia
  8.5. Others
     
9. Global Cardiovascular Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
  9.1. Hospital Pharmacies
  9.2. Retail Pharmacies
  9.3. Online Pharmacies
  9.4. Others
 
10. North America Cardiovascular Drugs Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
  10.1. Introduction
  10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       10.2.1. U.S.A
       10.2.2. Canada
       10.2.3. Mexico
  10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Cardiovascular Drugs Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         11.2.1. Brazil
         11.2.2. Venezuela
         11.2.3. Argentina
         11.2.4. Rest of Latin America
   11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Cardiovascular Drugs Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         12.2.1. Germany
         12.2.2. U.K        
         12.2.3. France
         12.2.4. Italy
         12.2.5. Spain
         12.2.6. Russia
         12.2.7. Poland
         12.2.8. Rest of Europe
   12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Cardiovascular Drugs Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         13.2.1. Japan
         13.2.2. China
         13.2.3. India
         13.2.4. Australia and New Zealand
         13.2.5. ASEAN
         13.2.6. Rest of Asia Pacific
   13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         14.2.1. GCC
         14.2.2. Israel
         14.2.3. South Africa
         14.2.4. Rest of MEA
   14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape  
   15.1. Global Landscape - Key Players, Revenue and Presence
   15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   15.3. Global Emerging Companies
   15.4.  North America - Market Share Analysis and Key Regional Players
   15.5.  Europe - Market Share Analysis and Key Regional Players
   15.6.  Asia Pacific - Market Share Analysis and Key Regional Players
   15.7.  Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Drug Types Offered and Financial Layouts)
   16.1. Bristol Mayor Squibb Company
         16.1.1. Company Overview
         16.1.2. Drug Type Portfolio
         16.1.3. SWOT Analysis
         16.1.4. Financial Overview
         16.1.5. Strategic Overview
   16.2. Pfizer Inc
         16.2.1. Company Overview
         16.2.2. Drug Type Portfolio
         16.2.3. SWOT Analysis
         16.2.4. Financial Overview
         16.2.5. Strategic Overview
   16.3. Bayer AG
         16.3.1. Company Overview
         16.3.2. Drug Type Portfolio
         16.3.3. SWOT Analysis
         16.3.4. Financial Overview
         16.3.5. Strategic Overview
   16.4. Janssen Pharmaceuticals, Inc
         16.4.1. Company Overview
         16.4.2. Drug Type Portfolio
         16.4.3. SWOT Analysis
         16.4.4. Financial Overview
         16.4.5. Strategic Overview
   16.5. Astrazenca
         16.5.1. Company Overview
         16.5.2. Drug Type Portfolio
         16.5.3. SWOT Analysis
         16.5.4. Financial Overview
         16.5.5. Strategic Overview          
   16.6. Sanofi
         16.6.1. Company Overview
         16.6.2. Drug Type Portfolio
         16.6.3. SWOT Analysis
         16.6.4. Financial Overview
         16.6.5. Strategic Overview      
   16.7. Novartis AG
         16.7.1. Company Overview
         16.7.2. Drug Type Portfolio
         16.7.3. SWOT Analysis
         16.7.4. Financial Overview
         16.7.5. Strategic Overview
   16.8. Merck & Co,Inc.
         16.8.1. Company Overview
         16.8.2. Drug Type Portfolio
         16.8.3. SWOT Analysis
         16.8.4. Financial Overview
         16.8.5. Strategic Overview
   16.9. Gilead Sciences,Inc.
         16.9.1. Company Overview
         16.9.2. Drug Type Portfolio
         16.9.3. SWOT Analysis
         16.9.4. Financial Overview
         16.9.5. Strategic Overview
   16.10.F.Hoffman-La Roche Ltd
         16.10.1. Company Overview
         16.10.2. Drug Type Portfolio
         16.10.3. SWOT Analysis
         16.10.4. Financial Overview
         16.10.5. Strategic Overview
   16.11.Amgen Inc
         16.11.1. Company Overview
         16.11.2. Drug Type Portfolio
         16.11.3. SWOT Analysis
         16.11.4. Financial Overview
         16.11.5. Strategic Overview
   16.12.Baxter International Inc
         16.12.1. Company Overview
         16.12.2. Drug Type Portfolio
         16.12.3. SWOT Analysis
         16.12.4. Financial Overview
         16.12.5. Strategic Overview
   16.13.C. H. Boehringer Sohn AG & Co KG
         16.13.1. Company Overview
         16.13.2. Drug Type Portfolio
         16.13.3. SWOT Analysis
         16.13.4. Financial Overview
         16.13.5. Strategic Overview
   16.14.Johnson & Johnson
         16.14.1. Company Overview
         16.14.2. Drug Type Portfolio
         16.14.3. SWOT Analysis
         16.14.4. Financial Overview
         16.14.5. Strategic Overview

17. Pre and Post COVID-19 Impact
   17.1. Positive influence on the healthcare industry
   17.2. The financial disruption of the manufacturing sector
   17.3. Impact of COVID-19 on emerging companies
   17.4. Significant mandates in the healthcare regulations initiated by administrations
   17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures